The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma.
Michael E. Williams
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Fangxin Hong
No relevant relationships to disclose
Brad S. Kahl
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Randy D. Gascoyne
Consultant or Advisory Role - Roche/Genentech
Lynne I. Wagner
No relevant relationships to disclose
John C. Krauss
No relevant relationships to disclose
Sandra J. Horning
Employment or Leadership Position - Genentech
Stock Ownership - Genentech